Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: Lance who wrote (242)	9/22/1998 9:10:00 AM
From: t.gawarecki	Read Replies (2) \| Respond to of 307

Received the 6 month update Letter from the President of SYBD, R. Nicora yesterday. Nothing new but is a good summary of progress forward. Dated 9-18-98 but has not been added to the web site yet. For anyone who does not know and is interested, SYBD has a web site at sybd.com Has some good information.......and in the Articles section has an Article co-authored by a poster here. Tom

To: Lance who wrote (242)	10/13/1998 9:36:00 AM
From: t.gawarecki	Read Replies (1) \| Respond to of 307

NEWS!.........Still waiting for one of those "milestones". Synthetic Blood International Inc. Retains Public Relations Firm Business Wire - October 13, 1998 09:20 KETTERING, Ohio--(BUSINESS WIRE)--Oct. 13, 1998--Synthetic Blood International Inc. (OTCBB:SYBD), has retained Royal Public Relations Co. of St. Louis to handle its public relations activities with investors, the news media, stock brokers and stock analysts. Royal Public Relations Co. was established 25 years ago by Donald L. Roth, its president. Prior to entering the public relations field, Roth was a reporter and editor for the Associated Press and the "St. Louis Globe-Democrat" and "Kansas City Star" newspapers. His company has handled public relations for several New York Stock Exchange and American Stock Exchange companies, plus Nasdaq-listed corporations. "We are pleased to add an experienced public relations arm to our company to help relate significant developments in the rebuilding of SYBD. Don Roth's experience and contacts will be invaluable as we seek to more effectively communicate achievement of major milestones over the next year," said Robert Nicora, president and chief executive officer of Synthetic Blood International. SYBD is developing Oxycyte(TM), a perfluorocarbon blood substitute emulsion; Fluorovent(TM), a perfluorocarbon liquid ventilation product, and an implanted biosensor for continuous monitoring of blood glucose levels in diabetics. Synthetic Blood International is located in Kettering, Ohio, with its West Coast offices based in Newport Beach, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company's web site is sybd.com and its e-mail address is sybd@siscom.net. CONTACT: Synthetic Blood International Inc. Joan Mahan, 800/809-6054